Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse. The Antwerp-based biotech said ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Sanofi in talks to sell 50% stake in Opella for €15 billion ($16.4 billion). Goldman Sachs and Morgan Stanley arrange €6 billion in debt financing for buyers. According to the Bloomberg report ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. This newsletter was penned in ...

For the past year, French pharmaceutical giant Sanofi has been searching for a buyer to take control of its consumer health business. That search may now be over. On Friday, Sanofi said it’s in ...

MA Fashion Communication: Fashion Image is for image-makers who want to innovate in their specialist field. From October 2024, you can only apply for a maximum of 3 postgraduate courses each year at ...

Sanofi Healthcare Bidders Revising Offers Over Talc Concerns CD&R, PAI look to exclude aspects of Gold Bond unit in bids Consumer business could be valued at €15 billion in a sale ...

GSK Plc, Sanofi, and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human ...

Sanofi is of­fload­ing its rare au­toim­mune dis­ease med­i­cine En­jay­mo to an Ital­ian phar­ma­ceu­ti­cal com­pa­ny for $825 mil­lion up­front.